WO2011061252A3 - Combination of alpha- 2 adrenergic receptor agonist and non-steroidal anti - inflammatory agent for treating or preventing an inflammatory skin disorder - Google Patents
Combination of alpha- 2 adrenergic receptor agonist and non-steroidal anti - inflammatory agent for treating or preventing an inflammatory skin disorder Download PDFInfo
- Publication number
- WO2011061252A3 WO2011061252A3 PCT/EP2010/067749 EP2010067749W WO2011061252A3 WO 2011061252 A3 WO2011061252 A3 WO 2011061252A3 EP 2010067749 W EP2010067749 W EP 2010067749W WO 2011061252 A3 WO2011061252 A3 WO 2011061252A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inflammatory
- skin disorder
- combination
- receptor agonist
- steroidal anti
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010800509257A CN102655881A (en) | 2009-11-18 | 2010-11-18 | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
RU2012124904/15A RU2532388C2 (en) | 2009-11-18 | 2010-11-18 | Combination of alpha-2-adrenergic receptor agonists and non-steroid anti-inflammatory drug for treating or preventing inflammatory skin injury |
CA2780586A CA2780586C (en) | 2009-11-18 | 2010-11-18 | Combination therapy for treating or preventing an inflammatory skin disorder |
BR112012011031A BR112012011031A2 (en) | 2009-11-18 | 2010-11-18 | method of treating or preventing an inflammatory skin disorder or a sign and / or symptom topically administrable composition for treating or preventing a disorder |
KR1020127015276A KR101457773B1 (en) | 2009-11-18 | 2010-11-18 | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti - inflammatory agent for treating or preventing an inflammatory skin disorder |
US13/510,302 US9186358B2 (en) | 2009-11-18 | 2010-11-18 | Combination therapy for treating or preventing an inflammatory skin disorder |
JP2012539326A JP2013511490A (en) | 2009-11-18 | 2010-11-18 | Combination therapy to treat or prevent inflammatory skin disorders |
MX2012005537A MX2012005537A (en) | 2009-11-18 | 2010-11-18 | Combination of alpha- 2 adrenergic receptor agonist and non-steroidal anti - inflammatory agent for treating or preventing an inflammatory skin disorder. |
AU2010320911A AU2010320911B2 (en) | 2009-11-18 | 2010-11-18 | Combination of alpha- 2 adrenergic receptor agonist and non-steroidal anti - inflammatory agent for treating or preventing an inflammatory skin disorder |
EP10777034A EP2501410A2 (en) | 2009-11-18 | 2010-11-18 | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EPEP09176392.0 | 2009-11-18 | ||
EP20090176392 EP2329849B1 (en) | 2009-11-18 | 2009-11-18 | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011061252A2 WO2011061252A2 (en) | 2011-05-26 |
WO2011061252A3 true WO2011061252A3 (en) | 2011-11-17 |
Family
ID=42077025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/067749 WO2011061252A2 (en) | 2009-11-18 | 2010-11-18 | Combination therapy for treating or preventing an inflammatory skin disorder |
Country Status (11)
Country | Link |
---|---|
US (1) | US9186358B2 (en) |
EP (2) | EP2329849B1 (en) |
JP (1) | JP2013511490A (en) |
KR (1) | KR101457773B1 (en) |
CN (1) | CN102655881A (en) |
AU (1) | AU2010320911B2 (en) |
BR (1) | BR112012011031A2 (en) |
CA (1) | CA2780586C (en) |
MX (1) | MX2012005537A (en) |
RU (1) | RU2532388C2 (en) |
WO (1) | WO2011061252A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014523908A (en) * | 2011-07-14 | 2014-09-18 | アラーガン インコーポレイテッド | Oxymetazoline gel composition and method of use |
WO2013159151A1 (en) * | 2012-04-27 | 2013-10-31 | Troy Laboratories Pty Ltd | Combination meloxicam and xylazine therapy in animals |
AU2014262960A1 (en) * | 2013-05-06 | 2015-11-26 | Allergan, Inc. | Alpha adrenergic agonists for the treatment of tissue trauma |
US20160166569A1 (en) * | 2013-07-26 | 2016-06-16 | Galderma Research And Development | Method for treating skin thickening |
US9937117B2 (en) * | 2015-07-09 | 2018-04-10 | Galderma S.A. | Method of reducing hair loss associated with chemotherapy |
US10874682B2 (en) * | 2016-08-04 | 2020-12-29 | Nestlé Skin Health Sa | Compositions and the use thereof for treating or preventing rosacea |
JP2021536439A (en) * | 2018-08-29 | 2021-12-27 | セリックス バイオ プライヴェート リミテッドCellix Bio Private Limited | Ophthalmic compositions and methods for the treatment of eye disorders and skin disorders |
CN109364207A (en) * | 2018-11-23 | 2019-02-22 | 上海松皓生物科技有限公司 | A kind of composition and preparation method and the application for the treatment of and alleviation acne |
JP2022531116A (en) | 2019-05-01 | 2022-07-06 | クレキシオ バイオサイエンシーズ エルティーディー. | How to treat pruritus |
WO2021061913A1 (en) * | 2019-09-27 | 2021-04-01 | Encube Ethicals, Pvt. Ltd. | Diclofenac sodium topical solution |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002011683A1 (en) * | 2000-08-03 | 2002-02-14 | Dow Pharmaceutical Sciences | Topical gel delivery system |
US20030087962A1 (en) * | 1998-10-20 | 2003-05-08 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
WO2004105703A2 (en) * | 2003-05-27 | 2004-12-09 | Sansrosa Pharmaceutical Development, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
FR2909876A1 (en) * | 2006-12-19 | 2008-06-20 | Galderma Res & Dev S N C Snc | Use of 2-(2-amino-3-benzoyl-phenyl)-acetamide and its derivatives for the preparation of a composition for the treatment of skin diseases e.g. rosacea, psoriasis or atopic dermatitis |
WO2009032223A1 (en) * | 2007-08-31 | 2009-03-12 | Galderma Laboratories L.P. | Improved brimonidine compositions for treating erythema |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3278447A (en) | 1963-12-02 | 1966-10-11 | Cloro Bac Products Inc | Process for stabilizing chlorine dioxide solution |
US3560501A (en) | 1966-09-15 | 1971-02-02 | Ciba Geigy Corp | Process for making dihydroquinazolines |
BG16042A3 (en) | 1968-11-12 | 1972-05-20 | Nans Ott | METHOD FOR OBTAINING NEW 2(1H)-QUINAZOLINONES |
US3594380A (en) | 1969-02-18 | 1971-07-20 | American Home Prod | Isoquinolin-1(2h)-ones |
BE766039A (en) | 1971-04-21 | 1971-09-16 | Labofina Sa | NEW POLYMERS CONTAINING PYRAZOLE UNITS AND PROCESS FOR PREPARING THESE POLYMERS. |
US3740442A (en) | 1972-01-14 | 1973-06-19 | Sandoz Ag | 2-isopropylaminobenzophenones in treating inflammation |
US4029792A (en) | 1972-02-29 | 1977-06-14 | Pfizer Inc. | (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents |
BE795970A (en) | 1972-02-29 | 1973-08-27 | Pfizer | NEW DERIVATIVES OF QUINOLEINE, QUINOXALINE AND QUINAZOLINE ER PHARMACEUTICAL COMPOSITION CONTAINING THEM |
US4164570A (en) | 1973-09-24 | 1979-08-14 | David Clough | Stabilized aqueous catecholamine solutions |
US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
US4285967A (en) | 1978-06-30 | 1981-08-25 | Estee Lauder Inc. | Cosmetic preparation for reducing redness of blemishes |
US4256763A (en) | 1978-09-19 | 1981-03-17 | Mchugh John E | Treatment of herpes simplex infections and acne |
JPS5798209A (en) * | 1980-12-09 | 1982-06-18 | Kowa Co | Remedy for dermatopathy for external use |
US5166331A (en) | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
IL92351A (en) | 1988-11-29 | 1994-02-27 | Allergan Inc Irvine | Aqueous opthalmic solutions containing stabilized chlorine dioxide and an inorganic salt |
FR2648709A1 (en) | 1989-06-23 | 1990-12-28 | Boehringer Ingelheim France | NOVEL USE OF 1-PHENYL-2-AMINOETHANOL DERIVATIVES AS HEALING MEANS |
US5204347A (en) | 1989-10-12 | 1993-04-20 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines |
US5077292A (en) | 1989-10-12 | 1991-12-31 | Allergan, Inc. | (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same |
US5198442A (en) | 1989-10-12 | 1993-03-30 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
US5326763A (en) | 1989-10-12 | 1994-07-05 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
US5112822A (en) | 1989-10-12 | 1992-05-12 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
US5021416A (en) | 1989-10-31 | 1991-06-04 | Allergan, Inc. | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure |
US5130441A (en) | 1990-02-06 | 1992-07-14 | Allergan, Inc. | Method for producing amino-2-imidazoline derivatives |
US5237072A (en) | 1990-02-06 | 1993-08-17 | Allergan, Inc. | Method for producing amino-2-imidazoline derivatives |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
DK196591D0 (en) | 1991-12-05 | 1991-12-05 | Mouritsen & Elsner Aps | APPLICATION OF A KNOWN CHEMICAL COMPOUND FOR THE PREPARATION OF A PHARMACEUTICAL PREPARATION FOR TOPICAL APPLICATION |
US5736165A (en) | 1993-05-25 | 1998-04-07 | Allergan | In-the-eye use of chlorine dioxide-containing compositions |
JP3683908B2 (en) | 1993-10-13 | 2005-08-17 | アラーガン、インコーポレイテッド | Method of using (2-imidazolin-2-ylamino) quinoxaline derivative |
US6323204B1 (en) | 1993-10-13 | 2001-11-27 | Allergan | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
US6117871A (en) | 1993-12-17 | 2000-09-12 | The Procter & Gamble Company | 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists |
WO1996013267A2 (en) | 1994-10-27 | 1996-05-09 | Allergan | Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma |
US5693647A (en) | 1994-12-22 | 1997-12-02 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
JPH08208487A (en) * | 1995-02-01 | 1996-08-13 | Sekisui Chem Co Ltd | Agent for external use for treating inflammatory dermatosis |
WO1996025163A1 (en) | 1995-02-14 | 1996-08-22 | Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center | Treatment of herpes simplex viruses |
JPH08259465A (en) * | 1995-03-27 | 1996-10-08 | Sekisui Chem Co Ltd | External preparation for treating skin desease |
US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
US5720962A (en) | 1995-10-04 | 1998-02-24 | Au Pharmaceuticals, Inc. | Analgesic lotion for hemorrhoids and method of making such lotion |
US6441047B2 (en) | 1995-11-17 | 2002-08-27 | Alcon Manufacturing Ltd.. | Combination therapy for treating glaucoma |
US5753637A (en) | 1996-10-09 | 1998-05-19 | Ideal Ideas, Inc. | Method of treating acne conditions |
US5916574A (en) | 1996-10-09 | 1999-06-29 | Ideal Ideas, Inc. | Method of treating natural poison skin conditions |
EP0969790A2 (en) | 1997-02-21 | 2000-01-12 | Beiersdorf Aktiengesellschaft | Compositions for treating acne rosacea |
JPH10265365A (en) * | 1997-03-19 | 1998-10-06 | Shiseido Co Ltd | External preparation for skin for pimple |
US6159944A (en) | 1998-02-27 | 2000-12-12 | Synchroneuron, Llc | Method for treating painful conditions of the anal region and compositions therefor |
EP1090630A4 (en) | 1998-03-11 | 2004-06-16 | Soken Kk | Skin normalizing agents |
US6432934B1 (en) | 1998-08-06 | 2002-08-13 | Advanced Vision Research | Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease |
IN185228B (en) | 1999-02-03 | 2000-12-09 | Bakulesh Mafatlal Dr Khamar | |
US20020197300A1 (en) | 1999-02-22 | 2002-12-26 | Schultz Clyde L. | Drug delivery system for anti-glaucomatous medication |
WO2000076502A1 (en) | 1999-06-11 | 2000-12-21 | The Ohio State University Research Foundation | Methods and compositions for treating raynaud's phenomenon and scleroderma |
US6147102A (en) | 1999-10-26 | 2000-11-14 | Curatek Pharmaceuticals Holding, Inc. | Clonidine preparations |
US20030077301A1 (en) | 1999-12-16 | 2003-04-24 | Maibach Howard I. | Topical pharmaceutical composition for the treatment of inflammatory dermatoses |
US6294553B1 (en) | 2000-02-15 | 2001-09-25 | Allergan Sales, Inc. | Method for treating ocular pain |
US6284765B1 (en) | 2000-04-27 | 2001-09-04 | The University Of North Texas Health Science Center At Fort Worth | (+) naloxone and epinephrine combination therapy |
US6444681B1 (en) | 2000-06-09 | 2002-09-03 | The Ohio State University Research Foundation | Methods and compositions for treating Raynaud's Phenomenon and scleroderma |
US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
US7211267B2 (en) | 2001-04-05 | 2007-05-01 | Collagenex Pharmaceuticals, Inc. | Methods of treating acne |
US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
US6680062B2 (en) | 2001-10-05 | 2004-01-20 | Color Access, Inc. | Anti-irritating rosacea treatment |
US20040266776A1 (en) | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
US7345065B2 (en) | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
US20040092482A1 (en) | 2002-11-07 | 2004-05-13 | Gupta Shyam K. | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions |
US20040156873A1 (en) | 2003-02-10 | 2004-08-12 | Gupta Shyam K. | Topically Bioavailable Acne and Rosacea Treatment Compositions |
US20040220259A1 (en) | 2003-04-04 | 2004-11-04 | Yu Ruey J. | Topical treatment of dermatological disorders associated with reactive or dilated blood vessels |
CA2525789A1 (en) | 2003-05-15 | 2004-12-02 | Cutanix Corporation | Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde |
US20050059664A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Novel methods for identifying improved, non-sedating alpha-2 agonists |
US20050020600A1 (en) | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
US7285544B2 (en) | 2003-11-18 | 2007-10-23 | Bernstein Eric F | Use of nitroxides in treating skin disease |
US20050147570A1 (en) * | 2004-01-06 | 2005-07-07 | Nordsiek Michael T. | Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne |
US7812049B2 (en) | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
BRPI0511519A (en) | 2004-05-25 | 2007-12-26 | Sansrosa Pharmaceutical Dev In | method for treating or preventing an inflammatory skin disorder and the symptoms associated with it, topical composition suitable for treating or preventing the symptoms of an inflammatory dermatological disorder, and packaging for a topical composition |
EP1841320A2 (en) | 2005-01-12 | 2007-10-10 | S.U.L.V.E. Ltd. | Methods and pharmaceutical compositions useful for treating psoriasis |
US20070082070A1 (en) | 2005-10-11 | 2007-04-12 | Stookey Evangeline L | Treating skin disorders |
AU2007223560A1 (en) | 2006-03-01 | 2007-09-13 | Tristrata, Inc. | Composition and method for topical treatment of tar-responsive dermatological disorders |
CA2645073A1 (en) | 2006-03-08 | 2007-09-13 | Nuviance, Inc. | Transdermal drug delivery compositions and topical compositions for application on the skin |
JP4091639B2 (en) * | 2006-03-16 | 2008-05-28 | 成紀 金 | Preventive agent and / or treatment agent for skin disorder caused by tyrosine kinase inhibitor |
BRPI0717769A2 (en) * | 2006-10-17 | 2013-11-05 | Nuvo Res | GEL FORMULATION, METHOD FOR TREATMENT OF OSTEOARTHRITIS IN AN INDIVIDUAL SUFFERING FROM ARTICULAR PAIN, AND USE OF SODIUM DICLOFENAC |
EP2090307A1 (en) | 2008-02-15 | 2009-08-19 | Bone Therapeutics | Pharmaceutical composition for the treatment or prevention of osteoarticular diseases |
US20090263489A1 (en) | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation |
-
2009
- 2009-11-18 EP EP20090176392 patent/EP2329849B1/en active Active
-
2010
- 2010-11-18 MX MX2012005537A patent/MX2012005537A/en not_active Application Discontinuation
- 2010-11-18 RU RU2012124904/15A patent/RU2532388C2/en not_active IP Right Cessation
- 2010-11-18 CN CN2010800509257A patent/CN102655881A/en active Pending
- 2010-11-18 US US13/510,302 patent/US9186358B2/en active Active
- 2010-11-18 KR KR1020127015276A patent/KR101457773B1/en not_active IP Right Cessation
- 2010-11-18 BR BR112012011031A patent/BR112012011031A2/en not_active IP Right Cessation
- 2010-11-18 AU AU2010320911A patent/AU2010320911B2/en not_active Ceased
- 2010-11-18 WO PCT/EP2010/067749 patent/WO2011061252A2/en active Application Filing
- 2010-11-18 JP JP2012539326A patent/JP2013511490A/en not_active Ceased
- 2010-11-18 CA CA2780586A patent/CA2780586C/en not_active Expired - Fee Related
- 2010-11-18 EP EP10777034A patent/EP2501410A2/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030087962A1 (en) * | 1998-10-20 | 2003-05-08 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
WO2002011683A1 (en) * | 2000-08-03 | 2002-02-14 | Dow Pharmaceutical Sciences | Topical gel delivery system |
WO2004105703A2 (en) * | 2003-05-27 | 2004-12-09 | Sansrosa Pharmaceutical Development, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
US20050276830A1 (en) * | 2003-05-27 | 2005-12-15 | Dejovin Jack A | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
FR2909876A1 (en) * | 2006-12-19 | 2008-06-20 | Galderma Res & Dev S N C Snc | Use of 2-(2-amino-3-benzoyl-phenyl)-acetamide and its derivatives for the preparation of a composition for the treatment of skin diseases e.g. rosacea, psoriasis or atopic dermatitis |
WO2009032223A1 (en) * | 2007-08-31 | 2009-03-12 | Galderma Laboratories L.P. | Improved brimonidine compositions for treating erythema |
Non-Patent Citations (2)
Title |
---|
DACHIR S ET AL: "Potential anti-inflammatory treatments against cutaneous sulfur mustard injury using the mouse ear vesicant model", HUMAN AND EXPERIMENTAL TOXICOLOGY, vol. 21, no. 4, 1 January 2002 (2002-01-01), pages 197 - 203, XP009132030, ISSN: 0960-3271 * |
JARVIS B ET AL: "TOPICAL 3% DICLOFENAC IN 2.5% HYALURONIC ACID GEL - A REVIEW OF ITS USE IN PATIENTS WITH ACTINIC KERATOSES", AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, vol. 4, no. 3, 1 January 2003 (2003-01-01), pages 203 - 213, XP008054056, ISSN: 1175-0561, DOI: 10.2165/00128071-200304030-00007 * |
Also Published As
Publication number | Publication date |
---|---|
CN102655881A (en) | 2012-09-05 |
AU2010320911B2 (en) | 2013-09-12 |
US9186358B2 (en) | 2015-11-17 |
WO2011061252A2 (en) | 2011-05-26 |
MX2012005537A (en) | 2012-06-12 |
JP2013511490A (en) | 2013-04-04 |
RU2012124904A (en) | 2013-12-27 |
KR20120104244A (en) | 2012-09-20 |
CA2780586C (en) | 2015-10-06 |
US20130116259A1 (en) | 2013-05-09 |
AU2010320911A1 (en) | 2012-05-17 |
CA2780586A1 (en) | 2011-05-26 |
KR101457773B1 (en) | 2014-11-03 |
EP2329849B1 (en) | 2015-04-29 |
RU2532388C2 (en) | 2014-11-10 |
EP2329849A1 (en) | 2011-06-08 |
BR112012011031A2 (en) | 2019-09-24 |
EP2501410A2 (en) | 2012-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011061252A3 (en) | Combination of alpha- 2 adrenergic receptor agonist and non-steroidal anti - inflammatory agent for treating or preventing an inflammatory skin disorder | |
MX2011008450A (en) | Agonists and antagonists of the s1p5 receptor, and methods of uses thereof. | |
WO2009089494A3 (en) | Pharmaceutical compositions | |
EP2190408A4 (en) | Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation | |
WO2010132882A3 (en) | Sublingual dexmedetomidine compositions and methods of use thereof | |
EA201290041A1 (en) | TREATMENT OF DISORDERS ASSOCIATED WITH MACROPHAGES | |
WO2011099832A3 (en) | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same | |
WO2010087964A3 (en) | Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof | |
WO2010077836A3 (en) | Pyrrolidine compounds which modulate the cb2 receptor | |
WO2012021629A3 (en) | Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease | |
WO2011085162A3 (en) | Topical transdermal dexmedetomidine compositions and methods of use thereof | |
WO2009153665A3 (en) | Inhibitors of the shiga toxins trafficking through the retrograde pathway | |
WO2008070268A3 (en) | Pharmaceutical compositions | |
WO2007138466A3 (en) | Pharmaceutical compositions comprising meloxicam and tramadol combination | |
CL2009000803A1 (en) | Use of a pegylated variant of igf-1 to treat, prevent a neuromuscular disorder; method for the treatment, prevention and / or delay of a neuromuscular disorder; composition comprising the modified igf-1 variant | |
WO2009063378A3 (en) | Olive oil formulation for pain relief | |
WO2009129494A3 (en) | Alpha and beta adrenergic receptor agonists for treatment of pain and/or inflammation | |
WO2010062581A3 (en) | A botanical composition for enhanced skin repair and uses thereof | |
WO2012050831A3 (en) | Combination treatment for dermatological conditions | |
WO2011014825A3 (en) | Antiangiogenic small molecules and methods of use | |
WO2009026446A8 (en) | Hdac inhibitors | |
WO2010116282A8 (en) | 4, 5-dihydro-1h-pyrazole compounds and their pharmaceutical uses | |
WO2011115688A3 (en) | Integrin interaction inhibitors for the treatment of cancer | |
CL2015000434A1 (en) | Method for the treatment, prevention or reduction of the severity of a non-neoplasic skin condition or disorder that comprises administering a retinoid-derived compound; Dermal composition comprising retinoid derivatives. | |
WO2012027482A3 (en) | Compounds, compositions and methods related to ppar antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080050925.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10777034 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010777034 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010320911 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2780586 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/005537 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2010320911 Country of ref document: AU Date of ref document: 20101118 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012539326 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4960/DELNP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20127015276 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012124904 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13510302 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012011031 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012011031 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120510 |